These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 35209783)
1. Tocilizumab effectiveness in mechanically ventilated COVID-19 patients (T-MVC-19 Study): a multicenter real-world evidence. Mohzari YA; Alamer A; Alattas M; Alrashed AA; Alshehab NA; Alkhaldi TK; Alamer AA; Asdaq SMB; Aljefri D; Alajami HN; Alsowaida YS; Mathew M; AlMusawa MI; Alomar M; Alharbi RY; Khuwaja M; Bamogaddam RF; Alharthi AH; Faqihi AY; Alrumayyan BF; Alshareef A; Alhassan BM; Damfu NY; Alajmi GS; Albujaidy A; Alghalbi M; Alajlan SA; Abraham I; Almulhim AS Expert Rev Anti Infect Ther; 2022 Jul; 20(7):1037-1047. PubMed ID: 35209783 [TBL] [Abstract][Full Text] [Related]
2. Tocilizumab for Treatment of Mechanically Ventilated Patients With COVID-19. Somers EC; Eschenauer GA; Troost JP; Golob JL; Gandhi TN; Wang L; Zhou N; Petty LA; Baang JH; Dillman NO; Frame D; Gregg KS; Kaul DR; Nagel J; Patel TS; Zhou S; Lauring AS; Hanauer DA; Martin E; Sharma P; Fung CM; Pogue JM Clin Infect Dis; 2021 Jul; 73(2):e445-e454. PubMed ID: 32651997 [TBL] [Abstract][Full Text] [Related]
3. Tocilizumab in the treatment of critical COVID-19 pneumonia: A retrospective cohort study of mechanically ventilated patients. Fisher MJ; Marcos Raymundo LA; Monteforte M; Taub EM; Go R Int J Infect Dis; 2021 Feb; 103():536-539. PubMed ID: 33333252 [TBL] [Abstract][Full Text] [Related]
4. A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial. Rilinger J; Kern WV; Duerschmied D; Supady A; Bode C; Staudacher DL; Wengenmayer T Trials; 2020 Jun; 21(1):470. PubMed ID: 32493514 [TBL] [Abstract][Full Text] [Related]
5. The COVIRL002 Trial-Tocilizumab for management of severe, non-critical COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial. Cotter A; Wallace D; McCarthy C; Feeney E; O'Neill L; Stack J; McCarthy G; Hussain R; Alvarez Barco E; Doran P; Mallon P Trials; 2020 Sep; 21(1):758. PubMed ID: 32883328 [TBL] [Abstract][Full Text] [Related]
6. Retrospective cohort study to assess the association between treatment with tocilizumab and mortality among mechanically ventilated patients with COVID-19. Skarbinski J; Liu L; Hong V; Amsden LB; Fireman BH; Yau VM; Incerti D; Qian L; Fischer H; Ackerson BK; Shaw SF; Tartof SY BMJ Open; 2022 Oct; 12(10):e060358. PubMed ID: 36316080 [TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial. Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543 [TBL] [Abstract][Full Text] [Related]
8. Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial. Salvarani C; Dolci G; Massari M; Merlo DF; Cavuto S; Savoldi L; Bruzzi P; Boni F; Braglia L; Turrà C; Ballerini PF; Sciascia R; Zammarchi L; Para O; Scotton PG; Inojosa WO; Ravagnani V; Salerno ND; Sainaghi PP; Brignone A; Codeluppi M; Teopompi E; Milesi M; Bertomoro P; Claudio N; Salio M; Falcone M; Cenderello G; Donghi L; Del Bono V; Colombelli PL; Angheben A; Passaro A; Secondo G; Pascale R; Piazza I; Facciolongo N; Costantini M; JAMA Intern Med; 2021 Jan; 181(1):24-31. PubMed ID: 33080005 [TBL] [Abstract][Full Text] [Related]
9. Tocilizumab treatment in COVID-19: A prognostic study using propensity score matching. Güçlü ÖA; Önal U; Akalın H; Öztürk NAA; Belik HÖ; Demirdöğen E; Dilektaşlı AG; Kazak E; Ocakoğlu G; Sağlık İ; Coşkun F; Ediger D; Heper Y; Ursavaş A; Yılmaz E; Uzaslan E; Karadağ M Adv Clin Exp Med; 2022 Nov; 31(11):1197-1206. PubMed ID: 35951629 [TBL] [Abstract][Full Text] [Related]
13. Tocilizumab treatment in critically ill patients with COVID-19: A retrospective observational study. Huang E; Isonaka S; Yang H; Salce E; Rosales E; Jordan SC Int J Infect Dis; 2021 Apr; 105():245-251. PubMed ID: 33609773 [TBL] [Abstract][Full Text] [Related]
14. Impact of Timing of Tocilizumab Use in Hospitalized Patients With SARS-CoV-2 Infection. Singh AK; Oks M; Husk G; Dechario SP; Mina B; Singh K; Kirschenbaum L; Carpati CM; Mahmoud O; Gabra NI; Ishikawa O; Altschultz E; Shah V; Mahajan A; Gautam A; Birnbaum B; Antonacci AC; Raoof S Respir Care; 2021 Dec; 66(12):1805-1814. PubMed ID: 34548407 [TBL] [Abstract][Full Text] [Related]
15. Effectiveness and safety of favipiravir compared to supportive care in moderately to critically ill COVID-19 patients: a retrospective study with propensity score matching sensitivity analysis. Alamer A; Alrashed AA; Alfaifi M; Alosaimi B; AlHassar F; Almutairi M; Howaidi J; Almutairi W; Mohzari Y; Sulaiman T; Al-Jedai A; Alajami HN; Alkharji F; Alsaeed A; Alali AH; Baredhwan AA; Abraham I; Almulhim AS Curr Med Res Opin; 2021 Jul; 37(7):1085-1097. PubMed ID: 33890544 [TBL] [Abstract][Full Text] [Related]
16. Tocilizumab in hospitalized patients with COVID-19: Clinical outcomes, inflammatory marker kinetics, and safety. Hill JA; Menon MP; Dhanireddy S; Wurfel MM; Green M; Jain R; Chan JD; Huang J; Bethune D; Turtle C; Johnston C; Xie H; Leisenring WM; Nina Kim H; Cheng GS J Med Virol; 2021 Apr; 93(4):2270-2280. PubMed ID: 33200828 [TBL] [Abstract][Full Text] [Related]
17. Tocilizumab administration for the treatment of hospitalized patients with COVID-19: A systematic review and meta-analysis. Kyriakopoulos C; Ntritsos G; Gogali A; Milionis H; Evangelou E; Kostikas K Respirology; 2021 Nov; 26(11):1027-1040. PubMed ID: 34605114 [TBL] [Abstract][Full Text] [Related]
18. Effectiveness of tocilizumab in the treatment of hospitalized adults COVID-19: A systematic review and meta-analysis. Zhang J; Chen C; Yang Y; Yang J Medicine (Baltimore); 2022 Mar; 101(9):e28967. PubMed ID: 35244063 [TBL] [Abstract][Full Text] [Related]
19. Tocilizumab for treatment of mechanically ventilated patients with COVID-19. Somers EC; Eschenauer GA; Troost JP; Golob JL; Gandhi TN; Wang L; Zhou N; Petty LA; Baang JH; Dillman NO; Frame D; Gregg KS; Kaul DR; Nagel J; Patel TS; Zhou S; Lauring AS; Hanauer DA; Martin E; Sharma P; Fung CM; Pogue JM medRxiv; 2020 Jun; ():. PubMed ID: 32577684 [TBL] [Abstract][Full Text] [Related]
20. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes. Price CC; Altice FL; Shyr Y; Koff A; Pischel L; Goshua G; Azar MM; Mcmanus D; Chen SC; Gleeson SE; Britto CJ; Azmy V; Kaman K; Gaston DC; Davis M; Burrello T; Harris Z; Villanueva MS; Aoun-Barakat L; Kang I; Seropian S; Chupp G; Bucala R; Kaminski N; Lee AI; LoRusso PM; Topal JE; Dela Cruz C; Malinis M Chest; 2020 Oct; 158(4):1397-1408. PubMed ID: 32553536 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]